STRO Stock Analysis: Sutro Biopharma | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 379m USD | 12M Return: 200.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.88M
Qual. Beats: 0
Rev. Trend: 13.1%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 7.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sutro Biopharma is a clinical-stage oncology company headquartered in South San Francisco that develops antibody drug conjugates (ADCs) using its proprietary cell-free protein synthesis platforms, XpressCF and XpressCF+. Its lead candidate, STRO-004, targets tissue factor (TF) for the treatment of multiple TF-expressing solid tumors, including non-small cell lung, head and neck squamous cell, cervical, colorectal, pancreatic, endometrial, and bladder cancers. The pipeline also includes STRO-003, a ROR1-directed ADC for solid and hematological cancers, and pneumococcal conjugate vaccine candidates (VAX-24 and VAX-31) developed with partner Vaxcyte, which are in Phase II/III clinical trials.
Sutro generates revenue primarily through research collaborations and licensing agreements rather than commercial product sales, with notable partners including Tasly Biopharmaceuticals (Greater China rights to STRO-002), Ipsen (STRO-003), and Astellas Pharma (immunostimulatory ADCs). Founded in 2003 and formerly known as Fundamental Applied Biology, the company went public on NASDAQ in September 2018. As a small-cap biotechnology firm, Sutros business model is characteristic of the pre-commercial biotech sector, where value is driven by pipeline progress, clinical trial readouts, and partnership milestones rather than recurring product revenue.
- STRO-002 luvelta Phase 2 ovarian cancer data readout
- Vaxcyte collaboration milestones supplement limited product revenue
- ADC competition from Daiichi AstraZeneca pressures pipeline valuation
| Net Income: -153.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.57 > 0.02 and ΔFCF/TA 10.90 > 1.0 |
| NWC/Revenue: 150.8% < 20% (prev 232.4%; Δ -81.60% < -1%) |
| CFO/TA -0.63 > 3% & CFO -151.6m > Net Income -153.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (13.1m) vs 12m ago 57.42% < -2% |
| Gross Margin: 93.27% > 18% (prev 89.14%; Δ 4.14% > 0.5%) |
| Asset Turnover: 35.36% > 50% (prev 20.67%; Δ 14.69% > 0%) |
| Interest Coverage Ratio: -2.83 > 6 (EBIT TTM -112.8m / Interest Expense TTM 39.9m) |
| A: 0.62 (Total Current Assets 221.0m - Total Current Liabilities 70.8m) / Total Assets 242.0m |
| B: -4.20 (Retained Earnings -1.02b / Total Assets 242.0m) |
| C: -0.40 (EBIT TTM -112.8m / Avg Total Assets 281.7m) |
| D: -0.22 (Book Value of Equity -66.9m / Total Liabilities 308.9m) |
| Altman-Z'' = -12.54 = D |
| DSRI: 0.61 (Receivables 12.5m/13.6m, Revenue 99.6m/66.4m) |
| GMI: 0.96 (GM 89.14% / 93.27%) |
| AQI: 2.74 (AQ_t 0.01 / AQ_t-1 0.00) |
| SGI: 1.50 (Revenue 99.6m / 66.4m) |
| TATA: -0.01 (NI -153.6m - CFO -151.6m) / TA 242.0m) |
| Beneish M = -1.99 (Cap -4..+1) = B |
As of August 02, 2026, the stock is trading at USD 24.17 with a total of 163,209 shares traded. Over the past week, the price has changed by +5.64%, over one month by -27.20%, over three months by -34.00% and over the past year by +200.14%.
Current recommended Stop Loss: 21.60 (which is 10.6% or 1.3 ATR below the current price).
Sutro Biopharma has received a consensus analysts rating of 3.70. Therefore, it is recommended to hold STRO.
- StrongBuy: 4
- Buy: 0
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 47.8 | 97.6% |
P/E Forward = 10.0301
P/S = 3.8062
P/B = 2.1114
Revenue TTM = 99.6m USD
EBIT TTM = -112.8m USD
EBITDA TTM = -106.1m USD
Long Term Debt = 6.03m USD (estimated: total debt 13.6m - short term 7.60m)
Short Term Debt = 7.60m USD (from shortTermDebt, last quarter)
Debt = 13.6m USD (from shortLongTermDebtTotal, last quarter) (leases 13.6m already included)
Net Debt = -188.9m USD (calculated: Debt 13.6m - CCE 202.6m)
Enterprise Value = 190.2m USD (379.1m + Debt 13.6m - CCE 202.6m)
Interest Coverage Ratio = -2.83 (Ebit TTM -112.8m / Interest Expense TTM 39.9m)
EV/FCF = -1.38x (Enterprise Value 190.2m / FCF TTM -137.4m)
FCF Yield = -72.24% (FCF TTM -137.4m / Enterprise Value 190.2m)
FCF Margin = -137.9% (FCF TTM -137.4m / Revenue TTM 99.6m)
Net Margin = -154.2% (Net Income TTM -153.6m / Revenue TTM 99.6m)
Gross Margin = 93.27% ((Revenue TTM 99.6m - Cost of Revenue TTM 6.70m) / Revenue TTM)
Gross Margin QoQ = 91.20% (prev 86.06%)
Tobins Q-Ratio = 0.79 (Enterprise Value 190.2m / Total Assets 242.0m)
Interest Expense / Debt = 292.3% (Interest Expense 39.9m / Debt 13.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -89.1m (EBIT -112.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.90 (Total Current Assets 221.0m / Total Current Liabilities 76.3m)
Debt / Equity = -0.20 (negative equity) (Debt 13.6m / totalStockholderEquity, last quarter -66.9m)
Debt / EBITDA = 1.78 (negative EBITDA) (Net Debt -188.9m / EBITDA -106.1m)
Debt / FCF = 1.38 (negative FCF - burning cash) (Net Debt -188.9m / FCF TTM -137.4m)
Total Stockholder Equity = -79.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -54.53% (Net Income -153.6m / Total Assets 242.0m)
RoE = 192.8% (negative equity) (Net Income TTM -153.6m / Total Stockholder Equity -79.7m)
RoCE = 153.2% (negative capital employed) (EBIT -112.8m / Capital Employed (Equity -79.7m + L.T.Debt 6.03m))
RoIC = -51.28% (negative operating profit) (NOPAT -89.1m / Invested Capital 173.8m)
WACC = 11.56% (E(379.1m)/V(392.8m) * Re(11.98%) + (debt cost/tax rate unavailable))
Discount Rate = 11.98% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 79.74 | Cagr: 40.36%
[DCF] Fair Price = unknown (Cash Flow -137.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.10 | # QB: 0
Revenue Correlation: 13.08 | Revenue CAGR: 6.56% | SUE: 0.41 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-2.39 | Chg30d=N/A | Revisions=+0% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-2.46 | Chg30d=N/A | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=-7.80 | Chg30d=-16.29% | Revisions=-25% | GrowthEPS=+51.8% | GrowthRev=-56.5%
EPS next Year (2027-12-31): EPS=-6.88 | Chg30d=-177.62% | Revisions=-25% | GrowthEPS=+11.8% | GrowthRev=-29.2%
[Analyst] Revisions Ratio: -40% (up=0, down=2)